Analisi critica di un campione di farmaci oncologici valutati dalla Commissione Tecnica Regionale della Regione Veneto

Autor: C. Alberti, G. Scroccaro, S. Adami
Rok vydání: 2013
Předmět:
Zdroj: Giornale Italiano di Health Technology Assessment. 6:1-10
ISSN: 2035-6129
2035-3510
DOI: 10.1007/s40269-013-0001-5
Popis: In recent years, anticancer drug treatment was the main driver of hospital pharmaceutical expenditure. This expenditure is likely to increase as a result on the one hand of the entry of new biotechnological drugs, more costly than traditional therapies, and, on the other hand, from the extension of indications of many drugs already on the market. The objective of this study is to analyze the main trials conducted on a sample of anticancer drugs evaluated by the Regional Committee of Veneto Region, highlighting their criticalities. In the last two years, 11 anticancer drugs have been evaluated for one or more therapeutic indications and 13 HTA reports have been produced. Overall, 33 major studies in support of the efficacy have been identified: nine uncontrolled studies, 20 randomized controlled trials (RCTs) and four retrospective analysis of RCTs. Excluding the uncontrolled studies, the overall survival was the primary efficacy endpoint in only 50 % of trials. Because of the availability of many new anticancer drugs, expenditure for their acquisition has increased in importance over the last years and it is necessary to assess correctly the innovation of new technologies and the benefits for patients.
Databáze: OpenAIRE
Externí odkaz: